2 recruiting, 1 not yet recruiting. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Dominik Paul Modest: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pre-Operative Treatment in REseCTable COlon CanceR mFOLFOXIRI, mFOLFOX-6, CAPOX - Colo-rectal Cancer, Colon Cancer | Phase 3 | Not yet recruiting | Dominik Paul Modest | 714 | 2025-04-01 | 2025-03-28 |
| Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer Panitumumab 20 milligram/ML, Bevacizumab, Trifluridine/Tipiracil Hydrochloride - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Dominik Paul Modest | 153 | 2021-12-17 | 2024-02-15 |
| Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) mFOLFOX6, mFOLFOXIRI, FOLFIRI - Colorectal Cancer | Phase 3 | Recruiting | Dominik Paul Modest | 507 | 2021-12-06 | 2025-12-12 |
Colorectal Neoplasms (2) · Colonic Neoplasms (1)
Fluorouracil (2) · Irinotecan (2) · Leucovorin (2) · Oxaliplatin (2) · Bevacizumab (1) · IFL protocol (1) · Trifluridine (1) · trifluridine tipiracil drug combination (1)
Germany (3)
Dominik Modest, Prof. Dr. (1) · Dominik Modest, Prof. Dr. med. (1)
PMID 35366831, PMID 35897060, PMID 41857556
2019 (1), 2023 (1)